Nordic Capital bids for Advanz Pharma in $2B tie-up
January 28, 2021
Nordic Capital has offered to buy Advanz Pharma, a specialty drug company focused on complex medicines, for $846 million. Advanz said its board of directors agreed to Nordic's cash offer of $17.26 per share. Reuters reported that the deal would be worth around $2 billion, including debt. The Carlyle Group and TDR were also said to be interested in Advanz, which was formed in 2015 from the merger of AMCO and Concordia Healthcare.